Phenotypic Knockout of CXCR4 by a Novel Recombinant Protein TAT/54R/KDEL Inhibits Tumors Metastasis

The chemokine receptor, CXCR4, and its specific ligand, CXCL12, have been proven to regulate the directional trafficking and invasion of breast cancer cells to sites of metastases, and similar phenomena have also been identified in many malignant tumors that aberrantly overexpress CXCR4. Therefore, blocking the interaction between CXCR4 and CXCL12 is considered a possible approach to efficiently prevent cancer metastasis. Employing a cellular phenotypic knockout strategy based on intrakines, we developed a novel recombinant chimeric protein, TAT/54R/KDEL, which contains three distinct functional domains: CXCL12/54R, a mutant of CXCL12 with CXCR4 antagonism, as well as HIV-derived TAT (47-57) and an endoplasmic reticulum retention four-peptide sequence KDEL that links at its NH2 and COOH termini, respectively. Using the MOLT-4 cell line, which expressed CXCR4 highly and stably in vitro, we determined that TAT/54R/KDEL was able to efficiently transfer into the endoplasmic reticulum of tumor cells, where it specifically binds to the newly synthesized CXCR4 and prevents the latter from reaching the surface. Chemotaxis assays showed that the cells treated with TAT/54R/KDEL failed to migrate toward CXCL12. Furthermore, we observed that the systemic treatment of TAT/54R/KDEL could impair lung metastasis in a highly metastatic mammary cancer cell line, 4T1 cells, with the decrease of CXCR4 on their membrane. Our results suggest that the phenotypic knockout strategy of CXCR4 using a novel recombinant protein TAT/54R/KDEL might be a possible approach for inhibiting relative tumor metastasis mediated by CXCR4/CXCL12 interaction. (Mol Cancer Res 2009;7(10):1613–21)

[1]  W. Marasco,et al.  Intracellular antibodies (intrabodies) and their therapeutic potential. , 2008, Handbook of experimental pharmacology.

[2]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[3]  M. Morris,et al.  Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation* , 2005, Journal of Biological Chemistry.

[4]  Tommy Nilsson,et al.  Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum , 1989, Cell.

[5]  H. Pelham.  Evidence that luminal ER proteins are sorted from secreted proteins in a post‐ER compartment. , 1988, The EMBO journal.

[6]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[7]  R. Edwards,et al.  HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. , 1999, Biochemical pharmacology.

[8]  Gunnar P. H. Dietz,et al.  Inhibition of Neuronal Apoptosis in Vitro and in Vivo Using TAT-Mediated Protein Transduction , 2002, Molecular and Cellular Neuroscience.

[9]  Steven F Dowdy,et al.  Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. , 2005, Advanced drug delivery reviews.

[10]  S. Ohta,et al.  Protection against ischemic brain injury by protein therapeutics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Ratajczak,et al.  Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.

[12]  F. Sharp,et al.  In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis , 2002, The Journal of Neuroscience.

[13]  M. Williams,et al.  Depletion of uracil-DNA glycosylase activity is associated with decreased cell proliferation. , 2005, Biochemical and biophysical research communications.

[14]  D. Sane,et al.  Intrabody and intrakine strategies for molecular therapy. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  J. Bahn,et al.  Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. , 2001, Free radical biology & medicine.

[16]  Xiao-Hong Li,et al.  Loss of C-terminal alpha-helix decreased SDF-1alpha-mediated signaling and chemotaxis without influencing CXCR4 internalization. , 2004, Acta pharmacologica Sinica.

[17]  S. Schwarze,et al.  In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. , 2000, Trends in pharmacological sciences.

[18]  M. Jackson,et al.  Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. , 1990, The EMBO journal.

[19]  E. Galun,et al.  Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  T. Springer,et al.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) , 1996, The Journal of experimental medicine.

[21]  M. Farquhar,et al.  Identification and Characterization of GIV, a Novel Gαi/s -interacting Protein Found on COPI, Endoplasmic Reticulum-Golgi Transport Vesicles* , 2005, Journal of Biological Chemistry.

[22]  F. Torti,et al.  Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines , 1998, Gene Therapy.

[23]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[24]  H. Ishida,et al.  Molecular cloning and characterization of a novel human beta1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. , 2006, Glycobiology.

[25]  E. Snyder,et al.  Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. , 2005, Cancer research.

[26]  Soo‐Young Choi,et al.  Transduction of Cu,Zn‐superoxide dismutase mediated by an HIV‐1 Tat protein basic domain into mammalian cells , 2000, FEBS letters.

[27]  Ed Roos,et al.  The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. , 2003, Cancer research.

[28]  J. Votaw,et al.  Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.

[29]  H. Klocker,et al.  The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. , 2004, Journal of experimental therapeutics & oncology.

[30]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[31]  F. Balkwill,et al.  Epithelial cancer cell migration: a role for chemokine receptors? , 2001, Cancer research.

[32]  S. Munro,et al.  A C-terminal signal prevents secretion of luminal ER proteins , 1987, Cell.

[33]  Sunghoon Kim,et al.  Aminoacyl-tRNA synthetase-interacting multifunctional protein 1/p43 controls endoplasmic reticulum retention of heat shock protein gp96: its pathological implications in lupus-like autoimmune diseases. , 2007, The American journal of pathology.

[34]  S. Dowdy,et al.  TAT-mediated protein transduction into mammalian cells. , 2001, Methods.